{"id":876377,"date":"2025-08-15T16:54:32","date_gmt":"2025-08-15T20:54:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/"},"modified":"2025-08-15T16:54:32","modified_gmt":"2025-08-15T20:54:32","slug":"nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/","title":{"rendered":"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, Aug. 15, 2025<\/span><\/span> \/PRNewswire\/ —<\/p>\n

\n

\n
\n \"LOGO
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A\/S (NYSE: NVO) between May 7, 2025<\/span> and July 28, 2025<\/span>, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than September 30, 2025<\/span>.<\/p>\n

So What: If you purchased Novo Nordisk securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next:\u00a0To join the Novo Nordisk class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=34168<\/a>https:\/\/rosenlegal.com\/submit-form\/?case_id=14243<\/a> or call Phillip Kim, Esq.<\/span> at 866-767-3653 or email\u00a0case@rosenlegal.com<\/a> for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than September 30, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020, founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Novo Nordisk’s growth potential. Notably, Novo Nordisk’s asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1<\/span> exclusion and overstated the likelihood that such patients would switch to Novo Nordisk’s branded alternatives. Further, defendants greatly overstated the potential GLP-1<\/span> market or otherwise, Novo’s capability to penetrate said markets to achieve continued growth. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Novo Nordisk class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=34168<\/a> or call Phillip Kim, Esq.<\/span> at 866-767-3653 or email case@rosenlegal.com<\/a> for more information.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0 Laurence Rosen, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 Phillip Kim, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0 275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0 New York, NY<\/span> 10016
\u00a0\u00a0\u00a0\u00a0\u00a0 Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0 Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0 Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0 case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 www.rosenlegal.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/nvo-investors-have-opportunity-to-lead-novo-nordisk-as-securities-fraud-lawsuit-302531276.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A\/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than September 30, 2025. So What: If you purchased Novo Nordisk securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the Novo Nordisk … <\/p>\n

Continue reading “NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876377","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A\/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than September 30, 2025. So What: If you purchased Novo Nordisk securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the Novo Nordisk … Continue reading "NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T20:54:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NVO Investors Have Opportunity to Lead Novo Nordisk A\\\/S Securities Fraud Lawsuit\",\"datePublished\":\"2025-08-15T20:54:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/\"},\"wordCount\":653,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/\",\"name\":\"NVO Investors Have Opportunity to Lead Novo Nordisk A\\\/S Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"datePublished\":\"2025-08-15T20:54:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NVO Investors Have Opportunity to Lead Novo Nordisk A\\\/S Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/","og_locale":"en_US","og_type":"article","og_title":"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A\/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than September 30, 2025. So What: If you purchased Novo Nordisk securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the Novo Nordisk … Continue reading \"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-15T20:54:32+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit","datePublished":"2025-08-15T20:54:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/"},"wordCount":653,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/","name":"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","datePublished":"2025-08-15T20:54:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvo-investors-have-opportunity-to-lead-novo-nordisk-a-s-securities-fraud-lawsuit-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NVO Investors Have Opportunity to Lead Novo Nordisk A\/S Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876377"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876377\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}